Nurix Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
Lead BTK degrader is advancing to phase III for CLL, showing strong efficacy and safety, with a new confirmatory trial against pirtobrutinib. Autoimmune and early-stage programs are progressing, and the company is well-funded with $650M in cash.
-
Degrader therapies in immunology offer advantages over inhibitors by eliminating entire protein functions, enabling targeting of challenging proteins like STAT6. Key programs, including STAT6 (with Sanofi), BTK, and IRAK4 (with Gilead), are advancing, with major clinical milestones expected this year.
-
Bexobrutideg achieved strong clinical results in CLL, with an 83% response rate and 22.1 months PFS, supporting pivotal and head-to-head phase III trials. The pipeline expands into autoimmune and CNS diseases, with robust financials and industry enthusiasm for the degrader class.
Fiscal Year 2025
-
Bexobrutideg demonstrated an 83% response rate and 22-month median PFS in heavily pretreated CLL, including those with CNS involvement and high-risk mutations, with a favorable safety profile. Waldenstrom's patients showed 75–83% response rates. The pivotal DAYBreak program is underway, with combination and front-line studies planned.
-
The company is advancing a pipeline of targeted protein degraders, with Bexovibart leading in CLL and autoimmune indications. Upcoming pivotal studies and ASH presentations will highlight efficacy, safety, and dose selection. Collaborations with Sanofi and Gilead expand the pipeline into STAT6 and IRAK-4 programs.
-
Long-term data on BTK degraders will be presented at ASH, with pivotal CLL trials advancing and a strong focus on triple-exposed patients. Platform expansion into autoimmune diseases and robust partnerships with Gilead and Sanofi are underway, supported by over $650 million in cash.
-
Targeted protein degradation is advancing in CLL with pivotal trials for Bexdeg, which shows high efficacy and selectivity. The pipeline includes inflammation and oncology programs, with strong financial backing and key data updates expected at ASH and in 2026.
-
Pivotal phase II trial for Bexobrutideg in relapsed/refractory CLL has begun, with a 600 mg dose selected for registrational studies based on strong efficacy, safety, and broad mutational coverage. Pipeline programs in STAT6 and IRAK4 degraders are advancing, and the company is well-funded through 2028.
-
BTK degradation offers a unique mechanism with superior potency and efficacy in autoimmune disease, with pivotal data expected in 2026. Collaborative IRAK4 and STAT6 programs focus on selectivity and safety, while strong cash reserves support independent and partnered development.
-
Bexobrutide is advancing into pivotal phase 2 and 3 CLL trials, supported by strong early efficacy and safety data. The pipeline includes multiple oncology and immunology assets, with key milestones expected at ESMO and other conferences. Cash runway extends into 2027, enabling independent execution of core studies.
-
Targeted protein degradation is enabling new therapies for B-cell malignancies, with Bexobrutideg showing high response rates and a favorable safety profile in resistant CLL. The pipeline includes promising programs in oncology and immunology, with global trials and key data readouts expected this year.
-
Targeted protein degraders show strong efficacy and safety in oncology and autoimmune indications, with Bexabrutadeg leading pivotal trials and demonstrating high response rates, including in resistant mutations. Pipeline innovation and strategic partnerships drive expansion into new modalities and indications.
-
Bexobrutideg, a novel BTK degrader, is advancing to a global Phase III trial targeting second-line CLL, with strong efficacy against resistance mutations and a favorable safety profile. The pipeline includes collaborations on IRAK4 and STAT6 degraders, with updates and broader expansion plans expected in the fall.
-
Bexobrutideg demonstrated high response rates and durable efficacy in heavily pretreated CLL and Waldenström's patients, with a favorable safety profile and rapid onset of action. Regulatory designations support accelerated pivotal trials in 2025, and the drug is positioned for broad market impact and combination strategies.
-
Key updates include phase 1A data for Bexdeg in CLL, with pivotal study plans and regulatory updates expected mid-year. STAT6 and IRAK4 degrader programs advance through partnerships, while expansion into autoimmune indications and a Cbl-b inhibitor in solid tumors highlight a diversified, capital-efficient pipeline.
-
The company is advancing its BTK degrader Bexobrutideg into pivotal trials, showing high response rates and a strong safety profile in CLL. Strategic partnerships with Gilead, Sanofi, and Pfizer support pipeline expansion, while additional programs target autoimmune and aggressive lymphoma indications.
-
NX-5948, a BTK degrader, is advancing through pivotal and confirmatory trials with strong efficacy in CLL and plans for label expansion. Autoimmune programs are progressing, with rapid readouts expected and first-in-class potential for hemolytic anemia. Financials support global development and key partnerships are advancing.
-
NX-5948 is advancing to pivotal trials with an accelerated approval path, showing strong efficacy and safety. The pipeline includes a stepwise I&I strategy, major partnered programs, and innovative DACs, with key data updates and catalysts expected at major conferences this year.
-
Significant regulatory and clinical progress was made for NX-5948, with strong efficacy in CLL and Waldenström's, and expansion into autoimmune indications underway. Partnerships with major pharma and a robust cash position support pivotal trials and pipeline growth in 2025.
Fiscal Year 2024
-
NX-5948 demonstrated high response rates and durable activity in heavily pretreated CLL and Waldenström's, with a favorable safety profile and robust CNS activity. Regulatory milestones set the stage for pivotal trials in 2025, while pipeline expansion targets autoimmune and additional hematologic indications.
-
NX-5948 is advancing toward pivotal trials in CLL, with new ASH data expected to confirm high response rates and durability. The pipeline includes expansion into non-Hodgkin lymphoma, autoimmune indications, and new assets like NX-2127 and a pan-BRAF degrader. INDs for STAT6 and IRAK4 are targeted for early 2025.
-
NX-5948, a BTK degrader, is advancing through phase I-B with strong efficacy in CLL and Waldenstrom's, overcoming resistance mutations and showing CNS activity. Pivotal trials are planned for 2025, supported by Fast Track and PRIME status, with a robust cash position enabling pipeline expansion.
-
NX-5948 is advancing toward pivotal trials in CLL, showing strong response rates and safety potential, with expansion into Non-Hodgkin’s and autoimmune indications. Competitive differentiation may emerge in safety and head-to-head trials. Pipeline progress includes NX-2127, NX-1607, and collaborations on STAT6 and IRAK4.
-
The conference highlighted a robust degrader platform, with NX-5948 showing strong efficacy and safety in CLL, aiming to supplant current BTK inhibitors. NX-2127 and NX-1607 expand the pipeline into aggressive lymphomas and immuno-oncology, with pivotal studies and new indications planned for next year.
-
NX-5948, a BTK degrader, is advancing to pivotal trials in 2025, showing a 70% response rate in heavily pretreated CLL and strong activity against resistance mutations. Partnerships with Gilead and Sanofi support pipeline expansion, and over $450M in cash extends runway into 2026.
-
NX-5948 is advancing toward a pivotal CLL trial in 2025, supported by strong response rates in advanced patients and a favorable safety profile. Expansion into earlier lines, combinations, and new indications—including CNS and autoimmune diseases—is underway, with significant updates and collaborations expected in 2025.
-
The event highlighted a robust pipeline in targeted protein degradation, with NX-5948 showing strong efficacy and safety in CLL, pivotal trials planned for 2025, and promising CNS activity. Strategic partnerships and a solid cash position support ongoing development.
-
NX-5948 achieved a 69.2% response rate in heavily pretreated CLL patients, including those with BTK resistance mutations, and showed rapid, durable, and deepening responses with a favorable safety profile. Plans include phase I-B expansion, pivotal trials, and combination studies.
-
BTK degrader programs are advancing with strong clinical data, including high response rates and efficacy in resistant and CNS-involved disease. Strategic collaborations and recent fundraising have strengthened the financial position, supporting further pipeline progress.